Announcement on acquisition of marketing authorization

Hirosaki LI announces that it has acquired the marketing authorization for the human (autologous) oral mucosa-derived epithelial cell sheet using human amniotic membrane substrate (brand name: Sakracy) as a regenerative medical product for the alleviation of adhesion on the ocular surface accompanying limbal stem cell deficiency in Japan.